Eastern Asia: Market for Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses 2022

Market Size for Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses in Eastern Asia

In 2021, after five years of growth, there was decline in the East Asian human and animal blood market, when its value decreased by -X% to $X. The total consumption indicated a resilient increase from 2012 to 2021: its value increased at an average annual rate of +X% over the last nine years. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2021 figures, consumption increased by +X% against 2013 indices. Over the period under review, the market reached the maximum level at $X in 2020, and then reduced in the following year.

Production of Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses in Eastern Asia

In value terms, human and animal blood production declined to $X in 2021 estimated in export price. Overall, production, however, recorded prominent growth. The pace of growth appeared the most rapid in 2014 with an increase of X%. Over the period under review, production reached the peak level at $X in 2020, and then shrank slightly in the following year.

Exports of Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses

Exports in Eastern Asia

In 2021, overseas shipments of human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses decreased by -X% to X tons, falling for the second year in a row after two years of growth. Overall, exports, however, enjoyed a prominent expansion. The most prominent rate of growth was recorded in 2016 when exports increased by X% against the previous year. The volume of export peaked at X tons in 2019; however, from 2020 to 2021, the exports stood at a somewhat lower figure.

In value terms, human and animal blood exports rose to $X in 2021. In general, exports, however, enjoyed a prominent expansion. The most prominent rate of growth was recorded in 2018 when exports increased by X%. The level of export peaked in 2021 and is expected to retain growth in the near future.

Exports by Country

China represented the key exporting country with an export of about X tons, which recorded X% of total exports. South Korea (X tons) ranks second in terms of the total exports with a X% share, followed by Hong Kong SAR (X%), Japan (X%) and Taiwan (Chinese) (X%).

From 2012 to 2021, the most notable rate of growth in terms of shipments, amongst the main exporting countries, was attained by South Korea (with a CAGR of +X%), while the other leaders experienced more modest paces of growth.

In value terms, South Korea ($X) remains the largest human and animal blood supplier in Eastern Asia, comprising X% of total exports. The second position in the ranking was held by China ($X), with a X% share of total exports. It was followed by Japan, with a X% share.

From 2012 to 2021, the average annual rate of growth in terms of value in South Korea totaled +X%. The remaining exporting countries recorded the following average annual rates of exports growth: China (+X% per year) and Japan (-X% per year).

Export Prices by Country

In 2021, the export price in Eastern Asia amounted to $X per ton, picking up by X% against the previous year. Overall, the export price showed a resilient expansion. The most prominent rate of growth was recorded in 2019 an increase of X% against the previous year. The level of export peaked in 2021 and is expected to retain growth in the immediate term.

There were significant differences in the average prices amongst the major exporting countries. In 2021, the country with the highest price was South Korea ($X per ton), while Hong Kong SAR ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by Japan (+X%), while the other leaders experienced more modest paces of growth.

Imports of Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses

Imports in Eastern Asia

Human and animal blood imports soared to X tons in 2021, with an increase of X% against the year before. In general, imports showed a strong increase. As a result, imports reached the peak and are likely to continue growth in the immediate term.

In value terms, human and animal blood imports soared to $X in 2021. Over the period under review, imports enjoyed a prominent increase. The most prominent rate of growth was recorded in 2017 with an increase of X%. The level of import peaked in 2021 and is expected to retain growth in the near future.

Imports by Country

In 2021, China (X tons) was the main importer of human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses, achieving X% of total imports. It was distantly followed by Japan (X tons), South Korea (X tons) and Taiwan (Chinese) (X tons), together generating a X% share of total imports. Hong Kong SAR (X tons) followed a long way behind the leaders.

China was also the fastest-growing in terms of the human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses imports, with a CAGR of +X% from 2012 to 2021. At the same time, Hong Kong SAR (+X%), Taiwan (Chinese) (+X%), South Korea (+X%) and Japan (+X%) displayed positive paces of growth. China (+X p.p.) significantly strengthened its position in terms of the total imports, while Taiwan (Chinese), South Korea and Japan saw its share reduced by -X%, -X% and -X% from 2012 to 2021, respectively. The shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, China ($X) constitutes the largest market for imported human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses in Eastern Asia, comprising X% of total imports. The second position in the ranking was taken by Japan ($X), with a X% share of total imports. It was followed by South Korea, with a X% share.

In China, human and animal blood imports increased at an average annual rate of +X% over the period from 2012-2021. The remaining importing countries recorded the following average annual rates of imports growth: Japan (+X% per year) and South Korea (+X% per year).

Import Prices by Country

The import price in Eastern Asia stood at $X per ton in 2021, dropping by -X% against the previous year. Import price indicated a perceptible increase from 2012 to 2021: its price increased at an average annual rate of +X% over the last nine-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2021 figures, human and animal blood import price decreased by -X% against 2018 indices. The pace of growth was the most pronounced in 2017 when the import price increased by X% against the previous year. The level of import peaked at $X per ton in 2018; however, from 2019 to 2021, import prices stood at a somewhat lower figure.

There were significant differences in the average prices amongst the major importing countries. In 2021, the country with the highest price was Japan ($X per ton), while Taiwan (Chinese) ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by South Korea (+X%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :